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Abstract: Glycosaminoglycans (GAGs) such as heparan sulfate (HS) interact with a number of factors in the extracellular 
matrix (ECM) and as a consequence play a key role in the metabolic processes occurring within the cell. The dynamic 
synthesis and degradation of HS (and all GAGs) are necessary for ensuring that optimal chains are present for these functions. 
The degradation of HS begins at the cell surface and finishes in the lysosome, after which components can be recycled. 
Deficiencies or mutations in the lysosomal enzymes that process GAGs result in rare Mucopolysaccharidoses disorders 
(MPSs). There are few treatments available for these genetically inherited diseases and those that are available often do not 
treat the neurological symptoms of the disease. In this review, we discuss the enzymes involved in the degradation of HS and 
their related diseases, with emphasis on those located in the lysosome. 
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INTRODUCTION 
Carbohydrates known as glycosaminoglycans (GAGs) 
are major components of the extracellular matrix (ECM). 
Each tissue contains a unique, dynamic and heterogeneous 
ECM that infers tissue specificity via interactions with 
signalling molecules. Despite the physiological importance 
of GAGs, their synthesis is not directly encoded by the 
genome. There has hence been a great deal of interest in this 
field, not just to pinpoint the distinct functions of each GAG, 
but also to establish how and why particular chains are 
synthesised and degraded. GAGs in the ECM are typically 
found linked to a protein, forming a proteoglycan (PG), and 
is therefore a result of a protein undergoing post-translational 
modification. These PGs can possess a single GAG chain or 
many of different types. Hyaluronan is the only GAG that is 
not synthesised while covalently attached to a core protein. 
GAGs are composed of alternating disaccharides containing 
an amino sugar and an uronic acid or galactose (Gal) residue. 
With the exception of hyaluronan, GAG chains are often 
modified which impacts the interactions capable with other 
molecules. Many enzymes participate in the synthesis and 
modification of GAGs, often together in protein complexes. 
This observation has led to the proposed existence of a 
“GAGosome”, comprising a complex of the enzymes 
required to synthesise a particular GAG [1]. The exact 
composition of such a complex or complexes remains 
unknown.  
Heparan sulfate (HS) is a linear GAG produced in the 
Golgi of all mammalian cells and is initially synthesised as 
alternating N-acetylglucosamine (GlcNAc) and glucuronic 
acid (GlcA) repeating disaccharides. Heparin is also 
composed of alternating GlcNAc and GlcA residues but is 
only produced by mast cells. HS is known to influence 
pathogen entry, inflammation, and cell growth and  
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migration, lending roles in disease and tissue development 
[2]. HS and the proteins which interact with and/or 
synthesise and degrade HS are therefore emerging targets in 
disease treatments. The ability to isolate or synthesise 
specific chains of HS or heparin allows the examination of 
the interactions between HS and the proteins involved in 
these biological processes. This has resulted in the 
development of HS and heparin libraries for probing these 
interactions [3]. Fully understanding the enzymes 
responsible for synthesising and degrading HS and heparin is 
therefore not just vital for designing therapeutics for their 
associated diseases, but also in the design and creation of 
larger optimized HS libraries. 
The enzymes responsible for degrading HS and their 
associated diseases will be discussed here. In addition, there 
will be a brief introduction into the enzymes responsible for 
the synthesis and modification of HS. For recent detailed 
reviews on the biological synthesis and modification of HS 
(and other GAGs), please see Ref. 4 and 5. 
 
HS SYNTHESIS 
The GAG-protein linkage typical of all sulfated GAGs (HS, 
chondroitin sulphate (CS) and dermatan sulphate (DS)) is 
synthesised first, which involves attachment of the sugars 
comprising a conserved tetrasaccharide to a specific serine 
residue in the protein core. This serine is part of the 
S[G/A]X[G/A] conserved signal sequence [6,7], where at 
least two acidic residues either precede the serine residue or 
surround it [8]. The initial tetrasaccharide is synthesised 
sequentially by a xylosyltransferase (XylT), 
galactosyltransferase I (GalT-I), galactosyltransferase II 
(GalT-II) and glucuronyltransferase I (GlcAT-I), forming 
glucuronic acid(β1-3)-galactose(β1-3)-galactose(β1-4)-
xylose(β1-O)-Ser. The donor sugars are all obtained from 
uridine diphosphate (UDP) linked substrates which are 
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synthesised in the cytosol and subsequently transported to 
the Golgi [9], except in the case of UDP-xylose (UDP-Xyl) 
which is converted from UDP-GlcA by UDP-GlcA 
decarboxylase in the ER and Golgi [10]. The conserved 
tetrasaccharide in the GAG-protein linkage can be modified 
by phosphorylation of the Xyl (by FAM20B) [11] and de-
phosphorylation of the Xyl (by 2-phosphoxylose 
phosphatase (XYLP)) [12]. The tetrasaccharide of CS or DS 
can also be modified by 6-O sulfation of Gal (by chondroitin 
6-sulfotransferase I (C6ST-I)) [13]  and 4-O sulfation of Gal 
[14]. These modifications to the tetrasaccharide in the GAG-
protein linkage are often important for the regulation of the 
type and length of GAG chain synthesised. 
Once the tetrasaccharide linker has been synthesised, 
GlcNAc is added to the terminus by 
N-acetylglucosaminyltransferase I (GlcNAcT-I), committing 
the GAG to being HS or heparin [15,16]. If 
N-acetylgalactosamine (GalNAc) is added to the terminus by 
N-acetylgalactosaminyltransferase I (GalNAcT-I), the GAG 
is committed to being CS or DS [17]. It has been proposed 
that the activities of these two transferases can actually be 
attributed to one enzyme with two functional domains, 
EXTL2 [18]. Extension of the HS polymer with repeating 
disaccharides of GlcNAc and GlcA (Figure 1) is conducted 
by the so-called HS polymerase, which exhibits both 
N-acetylglucosaminyltransferase II (GlcNAcT-II) and 
glucuronyltransferase II (GlcAT-II) activities. HS 
polymerase is a heterodimer encoded by the EXT1 and EXT2 
genes [19]. There are also three exostosin-like genes, 
EXTL1-3, which all have roles in HS polymerisation. 
The HS chain is heavily modified by a number of 
isoenzymes (depicted in Figure 2), yielding somewhat 
unique chains. GlcNAc of HS can be N-deacetylated and 
N-sulfated by four different GlcNAc 
N-deacetylase/N-sulfotransferases (NDSTs), each of which 
have high sequence similarity [20,21]. If GlcNAc residues 
have been deacetylated and sulfated, neighbouring D-GlcA 
residues can act as substrates for the glucuronyl 
C5-epimerase (GLCE) and be epimerised to L-iduronic acid 
(L-IdoA) [22]. HS can be O-sulfated by HS 
2-O-sulfotransferase (2-OST), HS 3-O-sulfotransferase 
(3-OST) and HS 6-O-sulfotransferase (6-OST), all of which 
utilise 3’-phosphoadenosine 5’-phosphosulfate PAPS as a 
sulfur donor. 2-OST sulfates IdoA and GlcA residues, with a 
preference towards IdoA [23]. In fact, the occurrence of 2-O 
sulfated GlcA in GAGs is rare. Seven human isoforms of 
3-OST sulfate glucosamine (GlcN), N-sulfoglucosamine 
(GlcNS) or N-sulfoglucosamine-6-sulfate (GlcNS6S) 
residues of HS and heparin, and each exhibit different 
substrate specificities and expression patterns in tissues 
[24,25]. Three isoforms of 6-OST sulfate GlcNAc and 
GlcNS residues of HS [26,27]. 6-O sulfation on the reducing 
side of IdoA or GlcA prevents 2-OST binding, implying that 
2-O sulfation must occur before 6-O sulfation [28]. 
HS can also be remodelled extracellularly by the two 
human endosulfatases (Sulfs), HSulf1 and HSulf2. These 
sulfatases remove the 6-O sulfate group from GlcNS6S 
residues, particularly in regions containing the disaccharide 
IdoA2S-GlcNS6S [29,30]. Overexpression of a quail 
orthologue (QSulf1) does not affect the level of the HS 
proteoglycan (HSPG) Glypican1 on the cell surface, 
inferring a role for these Sulfs in remodelling HS but not 
degradation [30]. Subsequently, de-sulfation of HS by the 
Sulfs disrupts interactions between HS and signalling 
molecules [31]. 
 
HS DEGRADATION 
Due to the number of biological processes HSPGs mediate, 
turnover is a tightly regulated and necessary process. HSPG 
degradation is conducted by a number of exo- and 
endo-glycosidases and sulfatases, both extracellularly and 
intracellularly. This degradation begins at the cell surface 
and finishes in the lysosome, after which components can be 
recycled. The mechanism whereby HSPGs are internalised 
by the cell is unknown but they are trafficked through the 
endocytic pathway thereafter. 
Figure 1. Extension of the HS polymer is conducted by HS 
polymerase. The repeating HS disaccharide unit is initially 
composed of (-4)-GlcA(β1-4)-GlcNAc(α1-). Sites which can be 
modified by HS modifying enzymes have been illustrated as R 
or R’. GlcA can also be epimerised to IdoA, which has not been 
depicted here. 
Figure 2. As the HS chain is extended, it is heavily modified by 
a number of isoenzymes. GlcNAc can be N-deacetylated and N-
sulfated by NDSTs, GlcA can be epimerised by GLCE, IdoA 
and GlcA can be sulfated by 2-OST, GlcNAc and GlcNS can be 
sulfated by the 6-OSTs and GlcN, GlcNS or GlcNS6S can be 
sulfated by the 3-OSTs. 
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HEPARANASES 
Heparanase-1 (Hep1) is an extra- and intra-cellular 
endo-β-glucuronidase which in general cleaves the β1-4 
GlcA linkage in GlcN6S-GlcA-GlcNS regions of HS, 
although this sequence alone is not sufficient and additional 
sulfation on this or the neighbouring sequence is essential 
[32]. Hep1 cleaves preferentially in highly sulfated regions 
of HS and the minimum oligosaccharide length it requires is 
a trisaccharide. The expression of Hep1 is tightly regulated. 
The Hep1 promoter is a “housekeeping” gene [33] with three 
Sp1 binding sites and four ETS-relevant elements (EREs), 
which are vital for basal activity. In fact, two additional 
EREs were discovered in the Hep1 promoter of a metastatic 
breast cancer cell line, suggesting that upregulation of Hep1 
(and therefore ECM remodeling) is a factor in metastasis 
[34]. Hep1 expression levels are highest in the placenta, 
spleen, lymph node, peripheral blood leukocytes, bone 
marrow and foetal liver [35]. The high expression levels in 
lymphoid tissues suggests Hep1 typically acts at sites of 
inflammation or injury, by degrading HS and attracting 
leukocytes to these sites [36]. Overexpression of Hep1 has 
been observed in the tumours of various tissues and 
laboratory metastatic cell lines, and mice inoculated with 
Hep1 overexpressing cells developed lung and liver 
metastases [35,37,38]. 
The human Hep1 cDNA was first reported independently 
by three groups, all of whom purified Hep1 from human 
tissues and used derived sequences to screen EST databases 
[35,37,39]. Identification of the Hep1 cDNA was confirmed 
when cell lysates and/or media from overexpressing insect, 
COS-7 or NIH/3T3 cells were able to degrade HS substrates 
at a low pH optimum. The cDNA encodes a 65 kDa 
precursor containing a secretion signal sequence and six 
predicted N-glycosylation sites. The 65 kDa precursor is 
proteolytically cleaved to 8 kDa and 50 kDa forms which 
heterodimerise and produce active enzyme [40]. The linker 
region between the 8 kDa and 50 kDa forms has been 
predicted to block the active site of Hep1, rendering the 
precursor inactive [41]. This was confirmed in the X-ray 
crystal structure of mature Hep1 [42]. The protease 
responsible for this processing is thought to be a 
cathepsin-L-like protease [43]. Site-directed mutagenesis 
studies of the precursor cleavage sites suggested a 
non-specific protease acted, and a hydrophobic residue was 
required at one of the sites. Cathepsin inhibitors prevented 
processing of the Hep1 precursor and cathepsin-L was able 
to process the recombinant Hep1 precursor to the active 
form. 
Hep1 appears to localise both in the lysosome and 
extracellularly. Immunofluorescence and GFP fusion studies 
indicated a localisation of Hep1 to acidic compartments 
within the cell [44]. These studies also demonstrated 
localisation to the Golgi, although it was suggested that 
transport to the Golgi was necessary for the proteolytic 
processing of Hep1 to the active enzyme. Hep1 can be 
endocytosed by primary human fibroblasts via an actin 
cytoskeleton pathway [45]. After endocytosis Hep1 doesn’t 
translocate to the lysosome, but instead resides in the 
cytoplasm and endosomes. This internalisation of Hep1 is 
mediated by HSPGs [46]. It has been suggested that 
extracellular Hep1 functions more in binding HS for 
endocytosis, whereas intracellular Hep1 is the catalytically 
active form, as indicated by localisation studies and optimal 
activity at low pH [44,47]. 
The existence of a Hep1 related protein, Heparanase-2 
(Hep2), was initially discovered by searching a then 
proprietary EST database with the Hep1 protein sequence 
[48]. Hep2 is alternatively spliced yielding three transcripts, 
which encode proteins of varying lengths. Hep1 and Hep2 
share 35% sequence identity but high expression levels of 
each are detected in different tissues. Hep2 expression is 
highest in the brain, mammary gland, prostate, small 
intestine, testis and uterus, and significant expression is 
observed in the tumours of tissues which normally have low 
expression [48]. Hep2 doesn’t appear to have enzymatic 
activity towards HS but has been shown to inhibit Hep1 
through its strong affinity to HS and Hep1 [49]. Hep2 is 
upregulated in some tumours, indicating a possible role in 
inhibiting Hep1-related cancers in this instance [48,49]. 
Connective tissue activating peptide-III (CTAP-III), a 
processing product of platelet basic protein (PBP), is an 8-10 
kDa protein with optimum heparanase activity at pH 6.8 
[50]. Inflammatory sites characteristically have a low pH, 
lending a role for CTAP-III in wound healing. The 
expression level in neutrophils of an 80 kDa CTAP-III 
isoform and Hep1 is comparable, but the activity of Hep1 is 
much higher [51]. It is not clear why neutrophils have 
multiple heparanase-active enzymes and little is known 
about CTAP-III. 
 
LYSOSOMAL DEGRADATION 
All of the enzymes which degrade HS in the lysosome are 
exo-acting, meaning they must act sequentially to fully break 
down the oligosaccharide chains. An example of the 
sequential breakdown of a HS chain by lysosomal enzymes 
is depicted in Figure 3. These enzymes contain 
phosphorylated mannose (Man) residues for targeting to the 
lysosome via the mannose-6-phosphate receptor (MPR). 
Genetically inherited deficiencies or mutations in the 
lysosomal enzymes that process GAGs results in the 
lysosomal storage disorders called Mucopolysaccharidoses 
(MPSs), where accumulation of incomplete degradation 
products in the lysosome is observed. Mutations located in 
the active site of these enzymes, or those which cause the 
enzyme to misfold (meaning it is targeted for proteosomal 
degradation rather than trafficked to the lysosome), can 
impair the enzyme function. The number or location of 
mutations in these lysosomal enzymes directly correlates 
with the severity of disease phenotype, with pathologies 
including respiratory problems, skeletal deformities and/or 
central nervous system (CNS) abnormalities [52]. The MPSs 
are therefore multisystem diseases which require input from 
a variety of different medical disciplines for diagnosis and 
treatment. The thirteen types of MPS are inherited and each 
one is related to a specific enzyme (Table 1). Nine of these 
enzymes are involved in the degradation of HS, either 
exclusively or in addition to other GAGs. 
There are currently a number of treatments available for 
some types of MPS, including enzyme replacement therapy 
(ERT) and haematopoietic stem cell transplantation (HSCT). 
The idea of molecular chaperones has been explored, where 
small molecules bind to the enzyme and promote the correct 
folding of mutants and/or aid delivery across the blood brain 
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Table 1. The lysosomal enzymes involved in the degradation of GAG and their associated MPS disorders. Reported incidence rates are 
from the Registry for Mucopolysaccharide and Related Diseases. The MPS V and MPS VIII nomenclature is no longer in use. MPS V 
was originally assigned to Scheie syndrome before it was realised that Hurler and Scheie are caused by mutations in the same enzyme. 
MPS VIII originated from a misdiagnosis and therefore misassignment to a new disease type. KS, keratan sulfate. 
 
 
Enzyme GAG Disease Incidence Treatment 
α-L-iduronidase HS and DS 
MPS I 
(Hurler, Hurler-Scheie 
or Scheie syndrome) 
1 in 100,000 ERT and HSCT 
Iduronate-2-sulfatase HS and DS 
MPS II 
(Hunter syndrome) 
1 in 100,000 ERT 
Sulfamidase HS 
MPS IIIA 
(Sanfilippo A 
syndrome) 
1 in 85,000 
(for all MPS 
III combined) 
No treatment 
available 
α-N-acetylglucosaminidase HS 
MPS IIIB 
(Sanfilippo B 
syndrome) 
Acetyl-CoA:α-glucosamide 
N-acetyltransferase 
HS 
MPS IIIC 
(Sanfilippo C 
syndrome) 
N-acetylglucosamine-6-
sulfatase 
HS 
MPS IIID 
(Sanfilippo D 
syndrome) 
N-sulfoglucosamine-3-sulfatase HS 
MPS IIIE 
(Sanfilippo E 
syndrome) 
N-acetylgalactosamine-6-
sulfatase 
KS and CS 
MPS IVA (Morquio A 
syndrome) 
Unknown ERT 
β-galactosamine KS 
MPS IVB (Morquio B 
syndrome) 
Unknown 
No treatment 
available 
N-acetylgalactosamine-4-
sulfatase 
CS and DS 
MPS VI (Maroteaux-
Lamy Disease) 
Unknown ERT and HSCT 
β-D-glucuronidase HS, CS and DS 
MPS VII  
(Sly syndrome) 
>1 in 
250,000 
HSCT 
Glucuronate-2-sulfatase HS, CS and DS Unknown - - 
Hyaluronidase Hyaluronan 
MPS IX (Natowicz 
syndrome) 
Unknown 
No treatment 
available 
 
barrier (BBB) [53]. As previously mentioned, mutations 
which cause misfolding of lysosomal enzymes often also 
prevent localisation to the lysosome. Schueler et al. noted 
that only 11-15% residual activity of glucosylceramide 
β-glucosidase (mutations of which cause Gaucher disease) in 
the lysosome is sufficient to prevent glucosylceramide 
accumulation [54]. Therefore, even if the folding of a small 
amount of a particular lysosomal GAG degrading enzyme is 
aided by a molecular chaperone and hence targeted to the 
lysosome, accumulation of the GAG can be prevented. An 
alternative treatment currently being explored is substrate 
reduction therapy (SRT). This approach uses small 
molecules that inhibit the enzymes involved early in the 
synthesis of the GAG of interest, thereby reducing the level 
of GAG requiring degradation. Gene therapy is also being 
investigated whereby the gene encoding the wild type 
enzyme is incorporated into the patient’s genome. Gene 
therapy methods may potentially allow permanent 
restoration of active enzyme expression, which would be an 
improvement over HSCT and ERT methods that require 
regular transfusions. 
 
GLYCOSIDASES 
Glycosidases (or glycoside hydrolyses) are a large family 
of enzymes responsible for cleavage of the glycosidic bond 
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linking a sugar to another sugar, protein or lipid. Hydrolysis 
can occur with either inversion or retention of 
stereochemistry at the anomeric position, and typically 
involves two carboxylate-containing residues in the enzyme 
active site. Glycosidases are classified into 135 families 
based on sequence similarity (which is catalogued in the 
Carbohydrate Active enZyme (CAZy) database [55]) and 
display a variety of structural folds. There are three 
lysosomal glycosidases which degrade HS oligosaccharides 
to monosaccharides: α-L-iduronidase (IDUA), 
β-D-glucuronidase (GUSB) and α-N-acetylglucosaminidase 
(NAGLU). 
 
IDUA 
IDUA (CAZy family GH39) cleaves the α-L-IdoA 
glycosidic bond in HS and DS and has been purified from a 
number of human tissues and recombinant cell lines [56,57]. 
The cDNA of IDUA encodes a 653 amino acid polypeptide 
chain containing a 26 amino acid signal sequence and six 
potential N-glycosylation sites [58]. IDUA isolated from 
liver displayed a low pH optimum, an increase in activity 
upon the addition of bovine serum albumin (BSA) and a 
preference for C6 sulfation on the neighbouring residue at 
the reducing end [59]. The activity of recombinant IDUA 
also increased upon addition of the reducing agent 
dithioerythritol (DTE) and the non-ionic detergent Triton 
X-100 [57]. It was thought that the addition of Triton X-100 
reduced aggregation of IDUA in the activity assays. 
The crystal structure of human IDUA was reported 
independently by two groups [60,61]. Both groups observed 
a Man residue of the N-glycan on amino acid Asn372 
interacting with the IDUA active site residues and, through 
de-glycosylation studies and inhibitor complexes, realised 
that this interaction aids substrate binding and therefore 
activity.  
A deficiency or mutations in IDUA has been linked to 
MPS I, also known as Hurler, Hurler-Scheie or Scheie 
syndrome [62]. Hurler, Hurler-Scheie and Scheie syndromes 
refer to the more severe, intermediate and mild forms of the 
disease respectively. Recombinant IDUA has been shown to 
be endocytosed by fibroblasts from MPS I patients via the 
MPR pathway and restore degradation of HS and DS [57]. 
MPS I is currently treated with HSCT or ERT (Laronidase; 
Aldurazyme®) or a combination thereof, with a combination 
being the recommended course of treatment [63,64]. It has 
also been shown that there is scope for gene therapy for 
treating this disorder [65]. 
 
GUSB 
GUSB (CAZy family GH2) cleaves the β-D-glucuronic 
acid glycosidic bond in HS, CS and DS and has been 
purified from a number of human tissues and recombinant 
cell lines [66,67]. GUSB localises both in the ER and 
lysosomes in a tissue-dependent manner. The level of murine 
GUSB in the ER of different tissues was shown to be 
dependent on the level of the ER membrane protein egasyn 
[68]. If GUSB is in excess of egasyn, it is transported to the 
lysosome. Egasyn binds to the C-terminal end of precursor 
GUSB, a region which is not present in lysosomal localised 
GUSB [69]. GUSB contains four N-glycosylation sites 
which are required for tetramerisation [70]. The X-ray 
crystal structure of tetrameric GUSB has been solved, which 
displays four separate active sites [71]. The active site of 
each monomer lies within a cavity formed between two 
monomers; molecular modelling indicates that each active 
site can independently bind substrates at the same time.  
A deficiency or mutations in GUSB has been linked to 
MPS VII, also known as Sly syndrome, a rare but fatal 
disease [72]. MPS VII is currently treated with HSCT, and 
the first example of ERT for MPS VII improved the 
symptoms of a severely affected patient [73]. It has also been 
shown that there is scope for gene therapy for treating this 
disorder [74,75]. 
 
NAGLU 
NAGLU (CAZy family GH89) cleaves the α-GlcNAc 
glycosidic bond in HS and has been purified from a number 
of human tissues and urine [76–80]. Northern blot analysis 
revealed expression of NAGLU resulted in the production of 
a single species across all tissues tested [79]. The structure of 
the Clostridium perfringens NAGLU homolog (with 30% 
amino acid sequence identity to human NAGLU) has been 
solved and used to determine a model structure for human 
NAGLU [81], although an experimentally determined 
structure is not yet solved. A deficiency or mutations in 
NAGLU has been linked to MPS IIIB (also known as 
Sanfilippo B syndrome) [82,83]. There are currently no 
treatments available for MPS IIIB, although a number of 
methods are being explored. The uptake of recombinant 
NAGLU has been observed in NAGLU-deficient cell lines 
and mice [84]. Uptake was observed in tissues expressing 
MPR, such as Kupffer and endothelial cells of the liver and 
macrophages of the spleen. Not surprisingly, uptake was not 
seen in hepatocytes, lymphocytes and epithelial cells of the 
kidney, which are all deficient in MPR. To avoid lack of 
cellular uptake of NAGLU due to the absence of recognition 
of mannose-6-phosphate, an insulin-like growth factor II 
(IGFII) fusion was designed [85,86]. MPRs bind IGFII at an 
alternative binding site allowing uptake in a variety of 
tissues. The NAGLU-IGFII fusion was injected directly into 
mice brain (thus bypassing the BBB) and endocytosis was 
observed in neurons and liver cells. Gene therapy has also 
been explored as a treatment for MPS IIIB, where an 
adeno-associated virus (AAV) vector system was used to 
deliver the NAGLU gene to the CNS and peripheral nervous 
system (PNS) of mice [87] and primates [88]. 
 
 
SULFATASES 
The sequences of sulfatases are highly conserved and 
arise from a common ancestral gene, which is most likely the 
same ancestral gene that encodes phosphatases as they share 
a common phosphatase-like structural fold [89–91]. The 
overall structure and active site residues of sulfatases are 
highly conserved in all organisms [92]. The N-terminus is 
typically composed of a ten stranded β-sheet flanked by α-
helices and contains the active site. The C-terminus of 
sulfatases has a conserved structure but not sequence; the 
structure is typically composed of a four stranded β-sheet 
flanked by α-helices. Although these evolutionary related 
sulfatases fundamentally catalyse the same reaction, they 
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Figure 3. An example of how the sequential degradation from the 
non-reducing end of the tetrasaccharide IdoA2S(α1-4)-
GlcNS3S(α1-4)-GlcA2S(β1-4)-GlcNAc6S would occur in the 
lysosome by HS degrading enzymes. The arrows illustrate which 
moiety of the sugar chain is cleaved by the corresponding enzyme, 
with exception of HGSNAT which catalyses the acetylation of 
GlcN to GlcNAc. 
 
each exhibit substrate specificity. All eukaryotic sulfatases 
(and some prokaryotic) contain a conserved C[X]PSR motif 
and a partially conserved AALLTGR auxiliary motif, where 
[X] is either Thr, Cys, Ser or Ala [93]. The conserved 
cysteine residue is oxidised by the formylglycine generating 
enzyme (FGE) in the ER, forming the formylglycine (FGly) 
residue required for enzymatic activity. Mutations in the 
FGE encoding SUMF1 gene cause the fatal lysosomal 
storage disorder Multiple Sulfatase Deficiency (MSD), 
where the activity of all sulfatases is diminished due to lack 
of FGly conversion [94–96]. There are five sulfatases which 
are involved in the degradation of HS in the lysosome: 
iduronate-2-sulfatase (IDS), glucuronate-2-sulfatase (GDS), 
N-sulfoglucosamine-3-sulfatase (GN3S), 
N-acetylglucosamine-6-sulfatase (GN6S) and heparan 
N-sulfatase (also known as sulfamidase). 
 
IDS 
IDS cleaves the C2 sulfate group from iduronate-2-
sulfate (Ido2S) at the non-reducing end of HS and DS. The 
2.3 kb full length IDS gene encodes a 550 amino acid 
precursor polypeptide containing a predicted 25 amino acid 
signal sequence and eight potential N-glycosylation sites 
[97]. Cleavage of the first eight amino acids after the signal 
sequence cleavage site is also thought to occur, which 
removes one of these predicted N-glycosylation sites. To 
characterise IDS, it has previously been purified from human 
urine, plasma and various tissues, and from the 
overexpression of recombinant protein in mammalian cell 
lines [98–105]. Purification from tissues or urine typically 
yielded multiple IDS isoforms. Two of these isoforms from 
liver were studied further [104]; both were formed from 42-
45 kDa and 14 kDa polypeptides and it was proposed that 
together they produced the active enzyme. Activity of liver 
IDS was dependent on the identity of the carbohydrate on the 
reducing side of Ido2S and was more active when this 
residue was sulfated at the C6 position.  
Hunter syndrome (also known as MPS II) is an X-linked 
recessive inherited disorder, the symptoms of which were 
first recorded in 1917 [106] before the disease was linked to 
IDS [98,107]. The severity of the disease is dependent on the 
type of genetic mutation the patients carry; these mutations 
include single or multiple base deletions or substitutions, 
gene rearrangements and complete deletions of the IDS gene 
[108]. The X-ray crystal structure of IDS has recently been 
solved [109] providing a rationalization to the pathologies of 
known mutations. Rearrangements and deletions of the IDS 
gene can also impact neighbouring genes, giving rise to 
Hunter syndrome patients with additional disease 
phenotypes. An example of this is a deletion spanning to and 
including the FMR2 locus [110,111]. Mutations in the FMR2 
gene are associated with Fragile X E (FRAXE) syndrome 
and together with Hunter syndrome may cause more severe 
mental retardation. The IDS gene is located within 80 kb of 
an IDS-related or ‘pseudogene’ (IDS2) [112]. This IDS2 
gene has sequence similarity to IDS and recombination of 
the two genes is present in some Hunter syndrome patients 
[113,114]. 
Hunter syndrome is currently treated with ERT where 
ELAPRASE® (idursulfase, Shire Human Genetic Therapies 
Inc., Lexington, USA) or Hunterase® (idursulfase beta, 
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Green Cross Crop., Yongin, Korea) is administered 
intravenously on a weekly basis. High doses of these drugs 
are potentially dangerous to patients and they do not appear 
to improve neurological impairments due to the inability of 
the drugs to cross the BBB [115,116]. Fusion of a 
monoclonal antibody raised against the human insulin 
receptor to recombinant IDS (HIRMAb-IDS) has been 
shown to improve the ability of IDS to cross the BBB in 
Rhesus monkeys [116,117]. Gene therapy has also been 
explored as a treatment for Hunter syndrome, where an AAV 
vector system was used to deliver the IDS gene to the CNS 
and liver of mice, with promising outcomes [118]. HSCT or 
bone marrow transplant (BMT) in Hunter syndrome patients 
has been relatively unsuccessful, with complications arising 
from the procedure and little improvement of symptoms 
observed in surviving patients [119]. 
 
GDS 
GDS cleaves the C2 sulfate group from the β-D-GlcA 
residues of HS, CS and DS [120]. For characterisation, GDS 
has been purified from chick embryo chondrocytes, human 
fibroblast cell lines and human tissues [120–122]. Liver 
isolated GDS displayed a native molecular mass of 63 kDa 
by gel filtration and 47 kDa and 19.5 kDa forms by 
SDS-PAGE [121]. This indicated a possible proteolytic 
processing event where the mature protein is eventually 
formed of a heterodimer. GDS demonstrated a low pH 
optimum and inhibition by NaCl and EDTA, typical 
characteristics of lysosomal sulfatases. Until recently the 
existence of the GDS gene remained elusive but it has since 
been established that arylsulfatase K (ARSK) and GDS are 
synonymous [123]. The ARSK gene encodes a 536 amino 
acid protein of 68-70 kDa when recombinantly expressed 
[124,125]. A deficiency in this enzyme has not been reported 
in any patients to date, although a mild phenotype is 
expected due to the rarity of sulfated GlcA residues. 
 
GN3S 
GN3S catalyses the removal of the C3 sulfate group from 
the rare N-sulfoglucosamine-3-sulfate (GlcNS3S) residues of 
HS. This sulfatase was first isolated from human urine, 
where it was shown to specifically cleave the C3 sulfate 
group from glucosamine-3-sulfate, but only when the amino 
group was also sulfated, and at an optimum pH of 6.3 [126]. 
What had previously been annotated as arylsulfatase G 
(ARSG) has now been assigned the enzymatic role of GN3S 
after ARSG-knockout mice accumulated HS chains with a 
terminal N-sulfoglucosamine-3-sulfate residue [127]. The 
ARSG sequence encodes a 525 amino acid and 62 kDa 
protein with 87% homology to the murine orthologue [128]. 
Murine ARSG is present in most tissues except the heart and 
lungs, and a processed product of 34 kDa is also present in 
high quantities in the liver and brain [129]. Subcellular 
fractionation of mouse liver tissue suggested there was pre-
lysosomal processing of ARSG. It has been proposed that the 
63 kDa isoform of ARSG is tightly membrane associated in 
the ER/Golgi where it is first cleaved to 44 kDa and 18 kDa 
forms, and then the 44 kDa form is cleaved again to 34 kDa 
and 10 kDa forms, all in-transit to the lysosome [129]. It was 
suggested that the proteases cathepsin B and/or L were 
involved in this processing, but not exclusively, and 
additional proteases were also likely to be involved. 
A deficiency in GN3S/ARSG has provisionally been 
assigned as MPS IIIE syndrome, although there have been 
no recorded patients suffering from MPS IIIE to date [127]. 
Early onset degeneration of the retina was observed in 
ARSG knockout mice [130] and mutations in the ARSG gene 
in American Staffordshire terrier (AST) dogs has been 
shown to cause ataxia and inherited late-onset neuronal 
ceroid lipofuscinosis (NCL) [131], indicating potential 
phenotypes of any yet unidentified MPS IIIE sufferers. 
 
GN6S 
GN6S catalyses the removal of the C6 sulfate group from 
glucosamine-6-sulfate (GlcN6S) and N-acetylglucosamine-
6-sulfatate (GlcNAc6S) residues of HS and KS [132–134]. 
However, β-N-acetylhexosaminidase A is able to remove 
GlcNAc6S from the non-reducing end of KS without the 
removal of the C6 sulfate by GN6S, thus bypassing the need 
for GN6S in KS degradation in vivo [135]. GN6S is also able 
to catalyse the removal of the C6 sulfate group from glucose-
6-sulfate in vitro [133]. For characterisation, GN6S has 
previously been purified from human urine and liver, rat 
skin, bovine kidney and from overexpression of recombinant 
protein using mammalian cell lines [133,136–140]. GN6S 
isoforms isolated from liver demonstrated a substrate-
dependent optimum activity at pH 3.9-5.7, enhanced activity 
with the addition of BSA and DTT, and inhibition by sulfate 
and phosphate ions and NaCl above 25 mM [141]. These 
liver isoforms were more active on GlcNAc6S than GlcN6S, 
and most active when GlcNS6S was at the non-reducing end 
of the trisaccharide GlcNS6S-IdoA2S-anhydromannitol-6-
sulfate. It has been postulated that the precursor GN6S 
polypeptide is cleaved yielding 32 kDa and 48 kDa 
polypeptides which interact to form mature GN6S [142]. 
GN6S has been linked to Sanfilippo D syndrome, also 
known as MPS IIID [143]. This rare disease has only 31 
reported sufferers and 23 different GNS (encoding GN6S) 
mutations reported thus far [144], explaining why this 
enzyme has been so little studied and why there is currently 
no treatment available for this disease. However, a colony of 
severe MPS IIID suffering goats has been established to 
study GN6S and design therapeutics [145]. Recombinant 
caprine GN6S expressed in CHO cells was able to restore the 
degradation of HS in MPS IIID fibroblasts and the 
degradation of HS in the organs of MPS IIID suffering goats 
[139,146,147]. 
 
Sulfamidase 
Sulfamidase cleaves the sulfate from the amino group of 
GlcNS residues of HS and has been purified from a number 
of human tissues and recombinant cell lines [148–150]. 
Sulfamidase is an N-sulfatase which has structural 
similarities to O-sulfatases, but there is a clear difference in 
the vicinity of the active site to accommodate the different 
substrate [151]. Mutational studies of the five predicted 
N-glycosylation sites of sulfamidase indicated that the 
N-glycans on at least two of the sites (Asn41 and Asn151) 
are required for protein folding and/or enzyme activity [149]. 
A deficiency or mutations in sulfamidase has been linked to 
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Sanfilippo A syndrome, also known as MPS IIIA [152]. 
Sulfamidase is a functional homodimer and some of the 
known MPS IIIA causing mutations disrupt the dimer 
interface and/or substrate access to the active site [151]. 
MPS IIIA is the most common of the Sanfilippo syndromes 
and there are a number of treatment options currently being 
investigated. There is evidence that injecting recombinant 
sulfamidase into the cerebrospinal fluid of MPS IIIA 
suffering mice reduces neurological symptoms, although this 
required regular injections and a considerable humoral 
response was detected [153]. A sulfamidase-IGFII fusion has 
also been designed with uptake in the brain of Rhesus 
monkeys looking promising [154]. Gene therapy treatment 
has also been explored with MPS IIIA. An adenovirus vector 
system was used to deliver both SGSH (encoding 
sulfamidase) and SUMF1 (encoding FGE) genes to the CNS 
[155] and a reduction in GAG storage in the lysosome was 
observed in the brain. A humoral response is often seen with 
human adenovirus gene transfer, so a canine adenovirus 
transfer has also been tested with promising outcomes [156]. 
Similarly, intravenous lentiviral-mediated SGSH gene 
delivery increased sulfamidase levels in many tissues in mice 
[157–159]. HSCT is an unpopular treatment for MPS IIIA 
and is not thought to improve neurological symptoms [160]. 
 
ACETYL-COA:α-GLUCOSAMIDE 
N-ACETYLTRANSFERASE 
Acetyl-CoA:α-glucosamide N-acetyltransferase (HGSNAT) 
catalyses the acetylation of GlcN residues in HS, after de-
sulfation by sulfamidase. The product of this acetylation, 
GlcNAc, can subsequently be cleaved from the HS chain by 
NAGLU. HGSNAT is the only HS lysosomal enzyme that 
isn’t directly involved in degradation. For characterisation, 
HGSNAT has been partially purified from human tissues and 
recombinant cell lines [161–164]. The HGSNAT gene 
product is not homologous to any other proteins, and is 
predicted to contain 11 transmembrane domains and five 
N-glycosylation sites [165]. The N-terminus of the protein is 
predicted to be lysosomal and the C-terminus cytosolic. 
HGSNAT is ubiquitously expressed in all tissues with higher 
expression levels in the heart, skeletal muscle, liver, 
leukocytes, placenta and kidneys [165,166]. HGSNAT 
transfers acetyl groups from the cytoplasm to the inside of 
the lysosome and onto GlcN using acetyl-coenzyme A 
(acetyl-CoA) as the donor [167]. Acetylation of HGSNAT 
has a neutral pH optimum and transfer to GlcN has a low pH 
optimum. 
The mechanism of action of HGSNAT is under debate 
and there are two proposed models. One model suggests a 
‘ping-pong’ double displacement mechanism where an 
active site His residue on the cytosolic side of HGSNAT is 
acetylated and then a conformational change takes place to 
present the acetylated-His on the lysosomal side for acetyl 
transfer to GlcN [168]. In support of this model it was 
proposed that HGSNAT is proteolytically processed to two 
domains (29 kDa and 48 kDa) in the lysosome, which are 
held together with disulfide bonds and eventually form a 
~440 kDa active oligomer [164]. It was suggested that this 
proteolytic processing occurs within a loop containing the 
critical His making it more flexible and susceptible to the 
proposed conformational change. Another model proposed is 
a ‘random-order ternary-complex’ mechanism which doesn’t 
involve an acetylated-His intermediate [169]. A group who 
support this mechanism agrees that HGSNAT is cleaved in 
the lysosome to 27 kDa and 44 kDa products, but concluded 
that this processing event is not necessary for HGSNAT 
activity [163]. Their kinetic studies suggested a random 
sequential mechanism and they were unable to detect an 
acetylated intermediate by radiolabelling, which would have 
confirmed the ping-pong mechanism. 
A deficiency of or mutations in HGSNAT has been 
linked to Sanfilippo C syndrome, also known as MPS IIIC 
[170]. It has been suggested that there are two classes of 
MPS IIIC patients, those that possess HGSNAT which 
cannot be acetylated and those that possess HGSNAT which 
can be acetylated but cannot transfer the acetyl group to 
GlcN [171]. Many of the missense HGSNAT mutations result 
in misfolded and/or mis-glycosylated protein, making these 
MPS IIIC patients good candidates for molecular chaperone 
therapy [172]. It has also been reported recently that MPS 
IIIC suffering mice not only present with lysosomal storage 
accumulation but with mitochondrial structural abnormalities 
in neurons [173]. 
 
CONCLUSION 
Knowledge of the enzymes which synthesise and degrade 
HS, and the ability to overexpress and purify them, has not 
only been critical for understanding the related genetic 
diseases, but also for probing the structure of HS and heparin 
itself. In recent years the research in this field has mostly 
focussed on those enzymes that synthesise and modify HS, 
and molecules which interact with HS to manipulate 
biological processes. However, the lysosomal enzymes 
which degrade HS (and additional GAGs) are fundamental to 
the recycling of HS and therefore the life of the cell. 
Deficiencies in these enzymes may be related to rare MPS 
disorders but these are multisystem, fatal diseases. There are 
few approved treatment methods for the majority of these 
diseases, and those that are available often produce 
detrimental side effects and are unable to improve 
neurological symptoms. A better understanding of the mode 
of action of these lysosomal enzymes will allow for the 
design of more optimal therapeutics such as molecular 
chaperones. 
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